BOOK A DEMO

Agreement*
* Required fields
Contact Us
ClearRead CT

The CT that sees beyond

In a typical CT study, lung nodules and abnormalities are often shielded by physical structures and even machine “noise.” The most skilled radiologists can identify irregularities on sight. Yet unfortunately, they’re also impacted by a heavy workload and significant time constraints. Riverain’s ClearRead CT suppression technology simply allows radiologists to get a more accurate read quicker.

The ClearRead CT advantage

  • Enterprise-wide capability
  • CT manufacturers & acquisition protocol agnostic
  • Supports standard, low-dose, non-contrast and contrast CT studies
  • Automatically detects nodules of all types (solid, part-solid, ground glass) at or above 5mm
  • Supports visualization of nodules smaller than 5mm
  • High throughput, scalable computation using off-the-shelf hardware with VM deployments
  • Provides differential measurements
CLEARREAD CT

ClearRead CT is the first FDA-cleared device to support concurrent reading, allowing for faster reading with proven, superior, automatic nodule detection performance for all nodule types, including solid, sub-solid and ground-glass nodules.

ClearRead CT Vessel Suppress

ClearRead CT Vessel Suppress produces a secondary series of CT images, suppressing vessels and other normal structures within the lungs to improve nodule conspicuity. The Vessel Suppress series gives users access to a truly unique and patented technology that aids in improving reading accuracy and efficiency. The processed series can be easily linked with the original CT series for synchronized scrolling.

ClearRead CT Results
29% Fewer Missed Nodules

CT Vessel Suppress in action

Vessel Suppress not only enables improved nodule detection by eliminating obscuring normal structures, it also allows improved nodule characterizations for all nodule types.1 Improved characterization derives in part from the ability for precise segmentation of nodule boundaries. Aside from volumetrics, the Vessel Suppress series enables a unique view of nodules. In these comparison videos, the images on the right display the significant ClearRead difference.

ClearRead CT Detect

After the vessels have been suppressed, ClearRead CT Detect leverages the vessel-suppression series to locate and characterize suspected nodules, enabling transparent, precise automatic measurements.

ClearRead CT Results
Graphic: 26% faster reads

CT Detect in action

Riverain’s CT Detect technology provides measurements for each detected region of interest including location, type, volume, maximum, minimum, average axial plane diameters, and nodule depth. Use the navigation arrows above the images to scroll and see the ClearRead difference.

Case Study
Our technology seamlessly processes CT scans from all 13 of the Einstein Medical Centers CT scanners, regardless of manufacturer or acquisition protocols.

The application enables identification of small nodules faster and more reliably, particularly for oncological patients.”

Terrance Matalon, MD
Chairman of Einstein Medical Center Philadelphia’s Department of Radiology
Dr. Terence Matalon standing in front of Einstein Medical Center
Dr. Terence Matalon standing in front of Einstein Medical Center

ClearRead CT Compare

ClearRead CT Compare extends Detect by automatically matching nodules found in a current exam to the same nodule in a prior exam, enabling efficient visual and volumetric comparisons.

CT Compare

CT Compare in action

For each image in this gallery, you can see the current exam on the left and the prior exam on the right. The image chips at the bottom provide a close-up view of the individual finding, along with extracted measurements. Use the navigation arrows above the images to scroll and see the ClearRead difference.

The clear choice for CT technology

EASY INSTALLATION

Our acquisition normalization technology supports rapid installation of software based on elimination of the requirement to tune to specific scanners.

EASY INSTALLATION

Installation and configuration of our software typically take as little as four hours. The simplicity of the ClearRead installation on site is based on Riverain’s image normalization technology that eliminates the need for tuning to specific manufacturers or imaging protocols. Using the existing PACS review station for image interpretation also simplifies deployment.

EASY INSTALLATION

Our acquisition normalization technology supports rapid installation of software based on elimination of the requirement to tune to specific scanners.

EASY INSTALLATION

Installation and configuration of our software typically take as little as four hours. The simplicity of the ClearRead installation on site is based on Riverain’s image normalization technology that eliminates the need for tuning to specific manufacturers or imaging protocols. Using the existing PACS review station for image interpretation also simplifies deployment.

SEAMLESS WORKFLOW

ClearRead CT provides a seamless workflow that allows specific exams, devices or patient demographics to be selectively processed or rejected.

SEAMLESS WORKFLOW

Through use of DICOM standards, advanced routing capability, and DICOM filtering tools, ClearRead CT provides seamless workflow. Our software can be installed on a stand-alone server, delivered by Riverain, or installed on a virtual machine. ClearRead content is read on existing PACS review stations, eliminating the need for costly dedicated workstations.

SEAMLESS WORKFLOW

ClearRead CT provides a seamless workflow that allows specific exams, devices or patient demographics to be selectively processed or rejected.

SEAMLESS WORKFLOW

Through use of DICOM standards, advanced routing capability, and DICOM filtering tools, ClearRead CT provides seamless workflow. Our software can be installed on a stand-alone server, delivered by Riverain, or installed on a virtual machine. ClearRead content is read on existing PACS review stations, eliminating the need for costly dedicated workstations.

ADVANCED TECHNOLOGY

ClearRead technology implements the latest artificial intelligence and deep learning technologies for optimized content, workflow, and results. 

ADVANCED TECHNOLOGY

ClearRead CT technology has surpassed the state-of-the-art by a significant margin based on a combination of frameworks, modeling, and computational ingenuity. While achieving high reliability and significant performance usually depends on substantial amounts of processing, our system can run on commodity hardware, without the need for special computer cards or large memory systems.

ADVANCED TECHNOLOGY

ClearRead technology implements the latest artificial intelligence and deep learning technologies for optimized content, workflow, and results. 

ADVANCED TECHNOLOGY

ClearRead CT technology has surpassed the state-of-the-art by a significant margin based on a combination of frameworks, modeling, and computational ingenuity. While achieving high reliability and significant performance usually depends on substantial amounts of processing, our system can run on commodity hardware, without the need for special computer cards or large memory systems.

PROVEN RESULTS

Our advanced AI imaging software is used by leading international healthcare organizations and is continually evaluated for its effectiveness.

PROVEN RESULTS

Ultimately, Riverain understands that the main concern of clinicians when adopting new software is knowing that it is properly verified and validated. Peer reviewed articles; third-party studies and reference accounts are essential to the integrity of our ClearRead AI technology. Our success is supported by ample clinical evidence.

PROVEN RESULTS

Our advanced AI imaging software is used by leading international healthcare organizations and is continually evaluated for its effectiveness.

PROVEN RESULTS

Ultimately, Riverain understands that the main concern of clinicians when adopting new software is knowing that it is properly verified and validated. Peer reviewed articles; third-party studies and reference accounts are essential to the integrity of our ClearRead AI technology. Our success is supported by ample clinical evidence.